IN8bio Expands Leukemia Clinical Trial, Adds Ohio State University as New Site
IN8bio, a clinical-stage biopharmaceutical company, has expanded its Phase 1 clinical trial for INB-100. The Ohio State University is now a new clinical site for the trial. This expansion aims to accelerate enrollment and completion of the study. INB-100 Clinical Trial The INB-100 trial is evaluating a donor-derived gamma-delta T cell therapy for leukemia patients […]
IN8bio Announces Major Advancements in Leukemia and Glioblastoma Treatments
On October 12, 2023, IN8bio, a pioneering clinical-stage biopharmaceutical company, made a significant announcement regarding its gamma-delta T cell therapies. The company has successfully completed the enrollment for its Phase 1 study of INB-100, a potential treatment for leukemia patients. This marks a significant step forward as INB-100 is being evaluated for its safety when […]
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial of a genetically modified […]